Is Foundayo (orforglipron) more effective than Wegovy (semaglutide) for weight loss?

Wegovy (semaglutide) is superior to Foundayo (orforglipron) for weight loss

Based on the most recent head-to-head evidence, Wegovy (oral semaglutide 25 mg) achieves significantly greater weight loss than Foundayo (orforglipron 36 mg/17.2 mg tablet), with a mean difference of -3.2% body weight and substantially better tolerability. 1

Weight Loss Efficacy

The 2026 population-adjusted indirect treatment comparison directly addressing your question found:

• Oral semaglutide 25 mg produced 3.2% greater body weight reduction compared to orforglipron 36 mg (the bioequivalent dose to Foundayo 17.2 mg tablet) 1
• This translates to clinically meaningful additional weight loss beyond what orforglipron provides
• The advantage held across both treatment-regimen and efficacy estimands 1

For context on absolute weight loss:

• Subcutaneous semaglutide 2.4 mg (Wegovy injection) achieved 14.9-16.0% weight loss at 68 weeks 2
• Orforglipron 36 mg achieved approximately 11.8% weight loss 3
• Oral semaglutide 25 mg would be expected to achieve ~15% weight loss based on the comparative data 1

Tolerability and Safety Profile

Foundayo has significantly worse tolerability:

• 4.1-fold higher odds of discontinuation due to any adverse event with orforglipron versus oral semaglutide 1
• 13.9-fold higher odds of discontinuation due to gastrointestinal adverse events 1
• Higher rates of gastrointestinal events overall (58-59% with orforglipron vs 37-45% with oral semaglutide in comparative trials) 4
• Greater mean pulse rate increase with orforglipron (3.7-4.7 bpm) versus semaglutide (1.0-1.5 bpm) 4

Cardiovascular Benefits

Wegovy has proven cardiovascular mortality and morbidity benefits that Foundayo lacks:

• The SELECT trial demonstrated that subcutaneous semaglutide 2.4 mg reduced major adverse cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke) by 20% (HR 0.80,95% CI 0.72-0.90) in patients with established CVD 2
• Semaglutide improved heart failure symptoms and physical limitations in patients with HFpEF 2
• No cardiovascular outcomes data exist for orforglipron 5

Cardiometabolic Profile

Network meta-analysis of cardiometabolic endpoints showed:

• Semaglutide formulations achieved higher cardiometabolic efficacy index scores than orforglipron across multiple parameters (weight loss, lipids, blood pressure, waist circumference) 6
• Orforglipron 36 mg had a CEI of 0.68 versus oral semaglutide's comparable performance 6

Critical Caveats

Foundayo-specific concerns:

• Not recommended in severe hepatic impairment (4.6-fold increase in drug exposure) 7
• Reduces efficacy of oral contraceptives—requires switching to non-oral contraception for 30 days after initiation and each dose escalation 7
• Nondose-dependent heart rate increases observed 5
• Small signal for mild pancreatitis 5
• Potential increased ventricular arrhythmia risk in heart failure with reduced ejection fraction (class concern) 5

Both medications:

• Require lifelong use—weight regain occurs rapidly upon discontinuation (11.6% regain at 52 weeks post-cessation for semaglutide) 2
• Share GLP-1 RA class warnings including thyroid C-cell tumors, pancreatitis, and gallbladder disease 7
• Must be used with reduced-calorie diet and increased physical activity 2, 8

Practical Considerations

Wegovy advantages:

• Proven cardiovascular risk reduction 2
• Better tolerability profile 1
• Greater weight loss efficacy 1
• No food/water restrictions for oral formulation
• Established safety profile with longer clinical experience

Foundayo's only potential advantage:

• Oral formulation without food/water restrictions (though oral semaglutide 25 mg also exists)
• This is negated by inferior efficacy and tolerability

Clinical Algorithm

Choose Wegovy (semaglutide) for:

• All patients seeking maximum weight loss
• Patients with established cardiovascular disease (proven mortality/morbidity benefit)
• Patients prioritizing treatment tolerability
• Patients with heart failure with preserved ejection fraction

Avoid Foundayo in:

• Severe hepatic impairment (contraindicated) 7
• Patients using oral contraceptives (unless willing to switch methods)
• Patients with heart failure with reduced ejection fraction (use with extreme caution)
• Patients with baseline tachycardia or cardiovascular concerns about heart rate elevation

The evidence unequivocally supports Wegovy as the superior choice for weight management based on greater efficacy, better tolerability, and proven cardiovascular benefits. 1, 2